Valuation: Regeneron Pharmaceuticals, Inc.

Capitalization 7.25TCr 6.15TCr 5.64TCr 5.31TCr 9.91TCr 6,90900Cr 9.99TCr 67TCr 26TCr 3,29000Cr 27TCr 27TCr 11,38700Cr P/E ratio 2026 *
18.5x
P/E ratio 2027 * 14.8x
Enterprise value 6.56TCr 5.57TCr 5.1TCr 4.81TCr 8.97TCr 6,25500Cr 9.04TCr 61TCr 24TCr 2,97900Cr 25TCr 24TCr 10,30800Cr EV / Sales 2026 *
4.13x
EV / Sales 2027 * 3.48x
Free-Float
72.33%
Yield 2026 *
0.55%
Yield 2027 * 0.62%
1 day-0.30%
1 week+0.50%
Current month+0.81%
1 month-4.82%
3 months-8.50%
6 months+5.67%
Current year-7.66%
1 week 701.99
Extreme 701.99
727.38
1 month 668.84
Extreme 668.845
767.21
Current year 668.84
Extreme 668.845
821.11
1 year 476.49
Extreme 476.4869
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 01/01/2001
Chief Executive Officer 73 08/01/1988
Director of Finance/CFO 55 05/02/2024
Director TitleAgeSince
Chairman 73 09/06/2023
Director/Board Member 85 01/06/1991
Director/Board Member 85 01/06/1991
Change 5d. change 1-year change 3-years change Capi.($)
-0.30%+0.50%+35.05%-4.40% 7.25TCr
+1.27%+3.29%+50.68%+179.92% 5.29TCr
-0.95%+45.80%+45.80%+45.80% 4.59TCr
-2.18%-20.79%-58.09%-67.83% 3.55TCr
+2.33%+5.74%+67.51%-36.26% 2.92TCr
-2.70%+11.80%+118.06%-58.82% 2.1TCr
+0.51%-3.59%+79.55%+123.14% 1.96TCr
+1.79%+3.27%+70.09%+56.33% 2TCr
-0.72%+1.38%+44.93%+86.60% 1.67TCr
-4.02%-6.25%+89.29%+353.58% 1.27TCr
Average -0.38%-0.43%+54.29%+67.81% 3.26TCr
Weighted average by Cap. -0.18%-0.59%+44.65%+49.27%

Financials

2026 *2027 *
Net sales 1.59TCr 1.35TCr 1.23TCr 1.16TCr 2.17TCr 1,51300Cr 2.19TCr 15TCr 5.71TCr 72TCr 5.96TCr 5.83TCr 2,49300Cr 1.76TCr 1.49TCr 1.37TCr 1.29TCr 2.4TCr 1,67600Cr 2.42TCr 16TCr 6.33TCr 80TCr 6.6TCr 6.46TCr 2,76200Cr
Net income 420.34Cr 356.7Cr 326.67Cr 308.01Cr 574.49Cr 40TCr 579.11Cr 3.87TCr 1.51TCr 19TCr 1.58TCr 1.54TCr 66TCr 516.4Cr 438.22Cr 401.32Cr 378.4Cr 705.78Cr 49TCr 711.44Cr 4.76TCr 1.86TCr 23TCr 1.94TCr 1.9TCr 81TCr
Net Debt -686.89Cr -582.89Cr -533.82Cr -503.32Cr -938.79Cr -65TCr -946.32Cr -6.33TCr -2.47TCr -31TCr -2.58TCr -2.52TCr -1,07900Cr -1.13TCr -961.05Cr -880.15Cr -829.86Cr -1.55TCr -1,07900Cr -1.56TCr -10TCr -4.07TCr -51TCr -4.25TCr -4.16TCr -1,77800Cr
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
11/26/11 712.77 $ -0.30% 12,27,186
08/26/08 714.89 $ +0.82% 5,89,041
07/26/07 709.10 $ -1.66% 7,74,679
06/26/06 721.05 $ +2.67% 7,39,914
05/26/05 702.27 $ -0.98% 6,42,799
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
712.77USD
Average target price
875.31USD
Spread / Average Target
+22.80%

Quarterly revenue - Rate of surprise